This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AMG 951, PRO 1762, Apo2L/TRAIL, rhApo2L/TRAIL, RG3639
Description: Dulanermin is a pro-apoptotic soluble protein based on naturally occurring Apo2L/TRAIL.Dulanermin is a dual PARA that directly activates the extrinsic apoptotic pathway viathe pro-apoptotic death receptors DR4 and DR5. Acting independently of p53, a tumorsuppressorprotein that is inactivated in many cancers, dulanermin has the potential to inducethe death of tumor cells that may otherwise be resistant to standard chemotherapy agents. Dulanermin may also activate the intrinsic apoptotic pathway through the mitochondrialamplification loop. Binding of dulanermin selectively induces apoptosis in cancer cellswhile sparing normal cells.
Deal Structure: Amgen is developing dulanermin in collaboration with Genentech.
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.
Partners: Roche Holding AG
Additional information available to subscribers only: